Date:3/24/2009

yond the control of the company. Actual results may differ materially from the expectations contained in the forward-looking statements. Factors that may cause such differences include the risks that: (i) each company may be unsuccessful in achieving the anticipated results of research and/or in commercially developing its products or in achieving market acceptance of new and relatively unproven technologies; (ii) each company will need to raise additional capital to meet its business requirements in the future and the company may not be able to do so on reasonable terms or at all; (iii) each company's proprietary intellectual property rights may not adequately protect its products and technologies; and (iv) each company expects intense competition in its target markets, including from companies that have much greater resources than the company, and there can be no assurance that the company will be able to compete effectively. More detailed information about the company and the risk factors that may affect the realization of forward-looking statements is set forth in each company's filings with the Securities and Exchange Commission, including each company's Annual Report on Form 10-K for the year ended December 31, 2007, and its subsequent Quarterly Reports on Form 10-Q filed with the SEC. Investors and security holders are urged to read this document free of charge on the SEC's web site at www.sec.gov. Each company does not undertake to publicly update or revise its forward-looking statements as a result of new information, future events or otherwise.

    Contact:

    Vida Communication (Media)                The Trout Group (Investors)
    On Behalf of WaferGen                     On Behalf of WaferGen
    Tim Brons                                 Peter Rahmer
    415-675-7400                              646-378-2973
    tbrons@vidacommu
'/>"/>
SOURCE  WaferGen Biosystems, Inc.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 
Related biology technology :

1. WaferGen to Present Data on SmartChip(TM) Real-Time PCR System at Cambridge Healthtech Institutes Quantitative PCR Conference
2. Data on WaferGens SmartChip(TM) System Presented at 16th International Molecular Medicine Tri-Conference
3. Data on WaferGens SmartChip Real-Time PCR System(TM) to be Presented at 16th International Molecular Medicine Tri-Conference
4. WaferGens SmartChip(TM) System Performance Successfully Demonstrated in Initial Phase of Alpha Testing Program
5. WaferGen Announces Third Quarter 2008 Financial Results
6. WaferGen to Present at the Rodman & Renshaw 10th Annual Healthcare Conference
7. NIH Awards Approximately $3M Grant for Research Involving WaferGens SmartChip(TM) Real-Time PCR System at the University of Pittsburgh
8. WaferGen to Present at the Seventh Annual BIO Investor Forum
9. WaferGen Announces Second Quarter 2008 Financial Results
10. WaferGen to Present at the Ninth Annual Beyond Genome Conference
11. WaferGen Announces Signing of Two Private Placements